Curis Announces Promising Results from Frontline AML Triplet Study

Curis Reports Positive Developments in AML Triplet Study

Curis, Inc. (NASDAQ: CRIS), a Massachusetts-based biotechnology company, is making waves in the realm of Acute Myeloid Leukemia (AML) treatment. Recently, at the 67th American Society of Hematology (ASH) Annual Meeting, the company unveiled updated data from its ongoing frontline AML triplet study (CA-4948-104). This vital research focuses on the compound emavusertib (CA-4948), a small molecule IRAK4 and FLT3 inhibitor, utilized in combination with venetoclax and azacitidine.

Emavusertib aims to provide new hope for AML patients who have achieved complete remission but remain minimal residual disease positive (MRD+). The study is designed to determine if adding emavusertib to the standard venetoclax and azacitidine combination can help these patients reach an undetectable MRD status (uMRD).

Study Overview

The frontline triplet study evaluates patients who previously completed a treatment regimen using ven-aza and are still MRD+. Curis presented data indicating that in the first two cohorts (receiving emavusertib for either 7 or 14 days within a 28-day cycle), 62.5% of participants achieved uMRD as of the latest data collected on October 12, 2025. Originally, four out of eight patients, or 50%, reached this critical milestone by July 2, 2025. The updated figures reported at ASH indicate one additional patient achieved uMRD, showcasing the efficacy of adding emavusertib to the treatment regimen.

James Dentzer, the CEO of Curis, expressed optimism regarding these results, stating, "These data are very promising and warrant further evaluation of additional triplet (ema/ven/aza) regimens to determine the optimal dose and schedule for safety and efficacy to improve patient outcomes in a difficult to treat population." This statement underscores the potential for new treatment protocols that could significantly benefit patients suffering from AML.

Implications and Future Directions

Curis’s research marks a significant advancement in the fight against AML, a notoriously challenging form of cancer. The promising results from this study may lead to further evaluations necessary to define the optimal treatment protocols for patients. With approximately 20,000 individuals diagnosed with AML each year in the U.S. alone, the implications of such advancements in treatment methodologies could be transformative.

Curis is currently also involved in various other studies to investigate emavusertib in different combinations, including the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) and the relapsed/refractory AML trials (CA-4948-102). Each of these studies aims to broaden the understanding of how emavusertib can be utilized effectively across different patient populations facing difficult-to-treat blood cancers.

Conclusion

Through a commitment to innovative biotechnology, Curis, Inc. continues to push boundaries in the development of targeted treatments for cancer. The promising updates from the frontline AML triplet study align with their dedication to enhancing patient outcomes and exploring new therapeutic avenues in managing AML. As research continues, the medical community watches closely, hopeful for breakthroughs that could lead to improved survival rates and quality of life for AML patients across the globe.